サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1606518

神経インプラントの世界市場-2024～2031年

Global Neurological Implants Market - 2024-2031

出版日
ページ情報
英文 176 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
神経インプラントの世界市場-2024～2031年
出版日: 2024年12月04日
発行: DataM Intelligence
ページ情報: 英文 176 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

神経インプラントの世界市場は、2023年に58億8,000万米ドルに達し、2031年には123億9,000万米ドルに達すると予測され、予測期間2024年にはCAGR 9.8％で成長する見込みです。

神経インプラントは、脳や神経系に外科的に埋め込む医療機器で、さまざまな機能を果たします。これらのインプラントは脳の特定部位を刺激し、パーキンソン病、てんかん、慢性疼痛などの神経疾患に伴う症状を緩和することができます。例えば、脳深部刺激（DBS）装置は、脳の標的領域に電気インパルスを送り、運動症状を効果的に管理するのに役立ちます。

神経インプラントは外部機器とのインターフェイスが可能で、障害を持つ人が自分の思考を使って義肢やその他の支援技術をコントロールできるようにします。これは多くの場合、ブレイン・コンピュータ・インターフェイス（BCI）によって実現され、神経信号を外部機器のコマンドに変換します。多くのBCIは、脳機能や神経疾患の根本的なメカニズムを調査するための研究環境で利用されています。神経活動を記録することで、研究者は脳の働きについて貴重な洞察を得ることができ、新たな治療戦略を開発することができます。

これらの装置は通常、特定の脳部位に取り付けられた一連の電極と、これらの電極から受信した信号を処理する制御ユニットで構成されています。電極は、電気インパルスを送ることで神経活動を刺激したり、研究や治療目的で記録したりすることができます。これらの要因が、世界の神経インプラント市場拡大の原動力となっています。

市場力学：

促進要因と阻害要因

神経疾患の発生率の上昇

神経疾患の罹患率の上昇が神経インプラントの世界市場の成長を大きく牽引しており、市場予測期間中も牽引していくと予測されています。

パーキンソン病、アルツハイマー病、てんかん、慢性疼痛などの神経疾患の罹患率の上昇は、世界の神経インプラント市場の成長を促進する大きな要因です。世界中で何百万人もの人々がこれらの疾患の影響を受けており、患者の予後を改善し、生活の質を向上させる効果的な治療オプションに対する需要が高まっています。

The Lancet Neurology誌に発表された重要な新しい研究によると、2021年には世界で30億人以上が神経疾患とともに生活していることが明らかになった。世界保健機関（WHO）との協力によるこの分析は、世界疾病・傷害・危険因子負担調査（GBD）2021データの一部です。

神経疾患は現在、世界的に病気や障害の主な原因となっています。神経疾患に起因する障害、疾病、早期死亡の全体的な負担は、障害調整生存年数（DALYs）で測定すると、1990年以来18％増加しています。

注目すべきは、神経疾患に関連した死亡や健康被害の80％以上が低・中所得国で発生していることです。治療へのアクセスには著しい格差があり、高所得国では人口10万人当たりの神経専門家の数が、低・中所得国に比べて最大70倍も多いです。これらの要因が、世界の神経インプラント市場を牽引しています。

脳深部刺激（DBS）装置を含む神経インプラントは、標的とする脳部位に電気インパルスを送ることで、運動障害やてんかんに伴う症状を緩和する効果が証明されています。これらの装置は、従来の薬物療法で効果が得られなかった患者にとって、有望な選択肢となります。

さらに、この業界の主要企業は、この世界神経インプラント市場を牽引する革新的な研究を目指し、製品を発表しています。例えば、2024年7月、Mint Neurotechnologies Ltd（MintNeuro）は、Biomedical Catalyst Feasibility Competition 2023を通じてInnovate UKから10万ポンドの助成金を受けた「EXPLORE」プロジェクトの立ち上げを発表しました。このイニシアチブは、前回のDREAMプロジェクトの成功を基に、ミントニューロ社の革新的な神経センシング技術の応用を、薬剤抵抗性てんかんに焦点を当てた当初のプロジェクト以外にも拡大することを目的としています。

また、2024年11月、イーロン・マスクの脳インプラント会社であるニューラルリンク社は、脳コンピューター・インターフェース（BCI）インプラントを、個人の思考でロボットアームを操作できるようにする新しいアプリケーションのテストを目的とした、新たな実現可能性研究の開始を発表しました。この進展は、マスク氏のソーシャルメディア・プラットフォーム「X」への投稿で共有され、ニューラリンク社はこの試験の承認と開始について興奮を表明しました。また、これらの要因はすべて、世界の神経インプラント市場に需要をもたらしています。

さらに、技術的進歩に対する需要の高まりも、神経インプラント市場の世界的拡大に寄与しています。

デバイスと処置の高コスト

デバイスと処置のコストが高いことが、神経インプラントの世界市場の成長を妨げます。脳深部刺激装置（DBS）などの神経デバイスの植え込みには、特殊な機器と高度な訓練を受けた外科医を必要とする複雑な外科手術が伴う。

HOSPIDIO.2024年のHOSPIDIO.Newsによると、インドにおける脳深部刺激療法（DBS）は、パーキンソン病、本態性振戦、ジストニアといった疾患の治療を求める患者にとって有効な選択肢です。この手術の費用は通常20,000ドルから28,000ドルで、およそ16,500,000円から23,000,000円です。費用は、使用するDBS装置の種類やブランドによって大きく異なります。装置によっては、より高度なものや付加的な機能がついているものもあり、全体的な費用が高くなることもあります。

これらの手術にかかる費用はかなり高額になることがあり、米国のような高所得国では3万5,000米ドルから10万米ドルに及ぶことが多いです。対照的に、インドのような国々では、費用は低く、通常15,000米ドルから30,000米ドルの間です。神経インプラントに関連する高額な費用は、特に資源が限られている地域では、ヘルスケアシステムにかなりの経済的負担を強います。このような経済的圧力は、神経学的治療よりも他の医療ニーズへの資金供給を優先させることにつながり、神経学的障害を患う患者の利用可能性とアクセスを制限することになります。したがって、上記の要因が神経インプラントの世界市場の潜在的成長を制限している可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 神経疾患の発生率上昇
    • 抑制要因
      • 機器や手順の高コスト
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 特許分析
  • 規制分析
  • SWOT分析
  • アンメットニーズ

第6章 製品タイプ別

  • 脳深部刺激装置
  • 迷走神経刺激装置
  • 脊髄刺激装置

第7章 材料別

  • シリコン
  • タングステン
  • プラチナイリジウム
  • ナノチューブ
  • その他

第8章 用途別

  • 慢性疼痛
  • パーキンソン病
  • てんかん
  • うつ
  • 本態性振戦
  • アルツハイマー病

第9章 エンドユーザー別

  • 病院
  • 神経科クリニック
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州地域
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況・シェア分析
  • M&A分析

第12章 企業プロファイル

  • Medtronic
    • 会社概要
    • 製品ポートフォリオと概要
    • 財務概要
    • 主な発展
  • Boston Scientific Corporation
  • NeuroPace Inc.
  • Abbott Laboratories
  • Aleva Neurotherapeutics
  • Renishaw PLC
  • NEVRO CORP.
  • Synapse Biomedical Inc.
  • LivaNova PLC

第13章 付録

目次
Product Code: MD8818

Overview

The global neurological implants market reached US$ 5.88 billion in 2023 and is expected to reach US$ 12.39 billion by 2031, growing at a CAGR of 9.8 % during the forecast period 2024-2031.

Neurological implants are medical devices that are surgically placed within the brain or nervous system, serving a variety of functions. These implants can stimulate specific regions of the brain to alleviate symptoms associated with neurological disorders such as Parkinson's disease, epilepsy, and chronic pain. For instance, deep brain stimulation (DBS) devices deliver electrical impulses to targeted areas in the brain to help manage motor symptoms effectively.

Neurological implants can interface with external devices, enabling individuals with disabilities to control prosthetic limbs or other assistive technologies using their thoughts. This is often achieved through brain-computer interfaces (BCIs), which convert neural signals into commands for external devices. Many neurological implants are utilized in research environments to investigate brain function and the underlying mechanisms of neurological disorders. By recording neural activity, researchers can gain valuable insights into brain operations and develop new treatment strategies.

These devices typically consist of a series of electrodes that are attached to specific brain areas, along with a control unit that processes the signals received from these electrodes. The electrodes can either stimulate neural activity by sending electrical impulses or record it for research and therapeutic purposes. These factors have driven the global neurological implants market expansion.

Market Dynamics: Drivers & Restraints

Rising Incidence of Neurological Disorders

The rising incidence of neurological disorders is significantly driving the growth of the global neurological implants market and is expected to drive throughout the market forecast period.

The rising incidence of neurological conditions such as Parkinson's disease, Alzheimer's disease, epilepsy, and chronic pain is a major factor driving the growth of the global neurological implants market. With millions of individuals affected by these disorders worldwide, there is an escalating demand for effective treatment options that can enhance patient outcomes and improve their quality of life.

A significant new study published in The Lancet Neurology reveals that over 3 billion people globally were living with a neurological condition in 2021. This analysis, which involved collaboration with the World Health Organization (WHO), is part of the Global Burden of Disease, Injuries, and Risk Factor Study (GBD) 2021 data.

Neurological conditions have now become the leading cause of ill health and disability worldwide. The overall burden of disability, illness, and premature death measured in terms of disability-adjusted life years (DALYs) attributable to neurological conditions has risen by 18% since 1990.

Notably, more than 80% of deaths and health loss associated with neurological disorders occur in low- and middle-income countries. There is a stark disparity in access to treatment; high-income countries have up to 70 times more neurological professionals per 100,000 people compared to their low- and middle-income counterparts. All these factors drive the global neurological implants market.

Neurological implants, including deep brain stimulation (DBS) devices, have proven effective in alleviating symptoms associated with movement disorders and epilepsy by delivering electrical impulses to targeted brain regions. These devices represent a promising option for patients who have not had success with traditional medications.

Furthermore, key players in the industry product launches and aiming for innovative studies that bwould drive this global neurological implants market. For instance, in July 2024, Mint Neurotechnologies Ltd (MintNeuro) announced the launch of the "EXPLORE" project, which is supported by a £100,000 grant from Innovate UK through the Biomedical Catalyst Feasibility Competition 2023. This initiative aims to build on the success of the previous DREAM project and expand the application of MintNeuro's innovative neural sensing technology beyond its initial focus on Drug-Resistant Epilepsy.

Also, in November 2024, Neuralink, Elon Musk's brain implant company, announced the launch of a new feasibility study aimed at testing its brain-computer interface (BCI) implant for a novel application enabling individuals to control a robotic arm using their thoughts. This development was shared in a post on Musk's social media platform, X, where Neuralink expressed excitement about the approval and initiation of this trial. Also, All these factors demand the global neurological implants market.

Moreover, the rising demand for technological advancements contributes to the global expansion of the neurological implants market.

High Costs of Devices and Procedures

The high costs of devices and procedures will hinder the growth of the global neurological implants market. The implantation of neurological devices, such as deep brain stimulators (DBS), involves intricate surgical procedures that necessitate specialized equipment and highly trained surgeons.

According to the HOSPIDIO. News in 2024, deep brain stimulation (DBS) surgery in India is a viable option for patients seeking treatment for conditions such as Parkinson's disease, essential tremor, and dystonia. The cost of this procedure typically ranges from $20,000 to $28,000, which is approximately ₹16,50,000 to ₹23,00,000. The cost can vary significantly depending on the type and brand of the DBS device used. Some devices are more advanced or come with additional features, which can increase the overall expense.

The costs for these surgeries can be quite significant, often ranging from USD 35,000 to USD 100,000 in high-income countries like the United States. In contrast, in countries like India, the costs are lower, typically between USD 15,000 and USD 30,000. The high costs associated with neurological implants place a considerable economic strain on healthcare systems, particularly in areas with limited resources. This financial pressure can lead to prioritization of funding for other medical needs over neurological treatments, thereby restricting availability and access for patients suffering from neurological disorders. Thus, the above factors could be limiting the global neurological implants market's potential growth.

Segment Analysis

The global neurological implants market is segmented based on product type, material, application, end-user, and region.

Product Type:

The deep brain stimulators segment is expected to dominate the global neurological implants market share

The deep brain stimulators segment holds a major portion of the global neurological implants market share and is expected to hold a significant portion of the global neurological implants market share during the forecast period.

Deep brain stimulation (DBS) involves the surgical implantation of electrodes into specific areas of the brain. These electrodes generate electrical impulses that modulate brain activity to treat various medical conditions. The electrical stimulation can also influence the cells and chemicals in the brain associated with these conditions.

The level of stimulation provided by DBS is regulated by a device similar to a pacemaker, which is implanted under the skin in the upper chest. A wire connects this device to the electrodes in the brain. DBS is an established treatment option for individuals with movement disorders, including essential tremor, Parkinson's disease, and dystonia.

Additionally, it is used for certain psychiatric conditions, such as obsessive-compulsive disorder (OCD), and has received approval from the Food and Drug Administration (FDA) for reducing seizures in patients with hard-to-treat epilepsy. DBS is typically recommended for patients whose symptoms are not adequately managed through medication alone.

Furthermore, key players in the industry research studies and product launches & approvals that would drive this segment growth in the global neurological implants market. For instance, in January 2024, researchers at the University of California San Diego developed an innovative neural implant that can capture information about brain activity from deep within the brain while resting on its surface. This breakthrough is made possible by a thin, transparent, and flexible polymer strip embedded with a dense array of graphene electrodes.

The technology represents a significant advancement toward creating a minimally invasive brain-computer interface (BCI) that can provide high-resolution data regarding deep neural activity through recordings taken from the brain's surface.

Also, in January 2024, Abbott announced that it had received approval from the U.S. Food and Drug Administration (FDA) to launch the Liberta RC deep brain stimulation (DBS) system. This device is notable for being the world's smallest rechargeable DBS system equipped with remote programming capabilities, specifically designed to treat individuals with movement disorders such as Parkinson's disease and essential tremor. These factors have solidified the segment's position in the global neurological implants market.

Geographical Analysis

North America is expected to hold a significant position in the global neurological implants market share

North America holds a substantial position in the global neurological implants market and is expected to hold most of the market share.

The prevalence of neurological disorders is steadily increasing due to various factors, including an aging population and lifestyle changes. For instance, as per Alzheimer's Disease Facts and Figures data in February 2021, the number of individuals living with Alzheimer's dementia in the United States is expected to rise from approximately 5.8 million in 2021 to 14.3 million by 2060, underscoring the urgent need for effective therapies to manage these conditions. Similarly, over 1 million Americans are diagnosed with Parkinson's disease, while around 5.1 million live with epilepsy.

Similarly, the incidence of neurological conditions such as Parkinson's disease, Alzheimer's disease, epilepsy, and chronic pain is steadily increasing. As per NCBI data in April 2022, In the U.S., millions are affected, leading to heightened demand for effective treatment options. For instance, approximately 6.5 million Americans aged 65 and older are living with Alzheimer's dementia as of 2022.

Deep brain stimulation (DBS) system equipped with sensing capabilities available on the market. This technology enables physicians to customize treatment for patients suffering from movement disorders, including Parkinson's disease, essential tremor, dystonia, and even epilepsy. In the United States, over 11 million individuals are affected by movement disorders, while approximately 3.4 million people live with epilepsy.

Moreover, in this region, a major number of key player's presence, well-advanced healthcare infrastructure, government initiatives & regulatory support, technological advancements, & investments and product launches & approvals would propel the global neurological implants market growth. For instance, in November 2024, Neuralink received authorization from Health Canada to commence clinical trials in Canada for its brain chip technology. This approval marks a significant step for the company as it expands its research efforts beyond the United States. Neuralink is now actively seeking volunteers to participate in these trials, which aim to evaluate the safety and effectiveness of its brain-computer interface (BCI) technology.

Also, in October 2022, Axoft officially launched its brain-machine interface (BMI) technology and announced that it has received the FDA Breakthrough Device designation. This designation is intended to expedite the development and review process for devices that have the potential to provide significant benefits to patients with serious conditions. The company has successfully secured $8 million in funding to support pre-clinical studies with the FDA and to scale up prototypes of its innovative neural implants, which are designed to be "as soft as the brain."

Thus, the above factors are consolidating the region's position as a dominant force in the global neurological implants market.

Asia Pacific is growing at the fastest pace in the global neurological implants market

Asia Pacific holds the fastest pace in the global neurological implants market and is expected to hold most of the market share.

The region is seeing a significant rise in neurodegenerative and psychiatric conditions, such as Parkinson's disease, Alzheimer's disease, and epilepsy. This growing incidence creates an urgent demand for effective treatment options, thereby boosting the need for neurological implants.

The aging population in Asia Pacific countries significantly contributes to the prevalence of neurological disorders, as older adults are more susceptible to these conditions. This demographic shift increases the demand for effective treatment options, including neurological implants.

According to The Lancet Regional Health - Western Pacific research data in 2021, China reported the highest age-standardized incidence and prevalence rates of Parkinson's disease (PD) among the G20 countries, with figures of 24.3 per 100,000 for incidence and 245.7 per 100,000 for prevalence. These rates significantly exceed the global averages. From 1990 to 2021, the age-standardized incidence of PD in China rose by 89.7%, while the age-standardized prevalence increased by 167.8%, marking the largest increase observed among the G20 nations. Thus, all these factors demand the neurological implant market.

The introduction of advanced technologies, such as MRI-safe brain implants, brain-computer interfaces (BCIs), and other innovative devices, enhances the treatment options available in the region. These advancements improve patient outcomes and encourage adoption among healthcare providers.

Furthermore, key players in the region more focus on research studies and product launches that would drive the neurological implant market. For instance, according to the NIPS data in April 2022, researchers from the University of South Alabama College of Medicine and the National Institute for Physiological Sciences in Japan have developed a novel method of deep brain stimulation (DBS) that is driven by motor cortical activity. This innovative approach has shown effectiveness in treating motor symptoms in monkeys with Parkinson's disease.

Also, in April 2024, Medtronic launched the NeuroSmart Portable MER Navigation System in India, specifically designed for deep brain stimulation (DBS) therapy in patients with Parkinson's disease. This advanced technology aims to enhance the precision and effectiveness of DBS procedures, which are used to alleviate motor symptoms associated with Parkinson's disease.

Thus, the above factors are consolidating the region's position as the fastest-growing force in the global neurological implants market.

Competitive Landscape

The major global players in the neurological implants market include Medtronic, Boston Scientific Corporation, NeuroPace Inc., Abbott Laboratories, Aleva Neurotherapeutics, Renishaw PLC, NEVRO CORP., Synapse Biomedical Inc., and LivaNova PLC among others.

Key Developments

  • In January 2024, Medtronic plc announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its Percept RC Deep Brain Stimulation (DBS) system. This rechargeable neurostimulator is the latest addition to the Medtronic Percept family, which also includes the Percept PC neurostimulator, BrainSense technology, and SenSight directional leads.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global neurological implants market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Material
  • 3.3. Snippet by Application
  • 3.4. Snippet by End-User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Incidence of Neurological Disorders
    • 4.1.2. Restraints
      • 4.1.2.1. High Costs of Devices and Procedures
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Patent Analysis
  • 5.5. Regulatory Analysis
  • 5.6. SWOT Analysis
  • 5.7. Unmet Needs

6. By Product Type

  • 6.1. Introduction
    • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 6.1.2. Market Attractiveness Index, By Product Type
  • 6.2. Deep Brain Stimulators*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Vagus Nerve Stimulators
  • 6.4. Spinal Cord Stimulators

7. By Material

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 7.1.2. Market Attractiveness Index, By Material
  • 7.2. Silicon*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Tungsten
  • 7.4. Platinum-iridium
  • 7.5. Nanotubes
  • 7.6. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Chronic Pain*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Parkinson's Disease
  • 8.4. Epilepsy
  • 8.5. Depression
  • 8.6. Essential Tremor
  • 8.7. Alzheimer's Disease

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Neurology Clinics
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Spain
      • 10.3.7.5. Italy
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. South Korea
      • 10.5.7.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Medtronic*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Boston Scientific Corporation
  • 12.3. NeuroPace Inc.
  • 12.4. Abbott Laboratories
  • 12.5. Aleva Neurotherapeutics
  • 12.6. Renishaw PLC
  • 12.7. NEVRO CORP.
  • 12.8. Synapse Biomedical Inc.
  • 12.9. LivaNova PLC

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us